Health Innovation Oxford and Thames Valley (previously Oxford AHSN) Final evaluation report of e-Stroke (as part of the AI in Health and Care Award)

Effectiveness: Brainomix 360 Stroke is associated with a significant increase in rates of MT and a reduction in DIDO times at ASCs. There is a relationship between time since implementation and time to treatment, with ASCs using Brainomix 360 Stroke for longer observing a bigger decrease in DIDO time.

Accuracy and Safety: The technology is seen as straightforward to use and reliable, processing over 97% of scans in an average time of 4 minutes. Brainomix 360 Stroke is perceived as a useful clinical decision support tool, and most clinicians opt to continue using the software with use increasing over time.

Value: Brainomix 360 Stroke is associated with a financial benefit in the region of 1.25 to 1.4 times the cost of implementing the technology, and with health benefit in the region of 1.17 to 1.35 times the cost of implementation.

Fit, feasibility and sustainability of scale-up: The continued and consistent use of Brainomix 360 Stroke across evaluation sites demonstrates acceptance and usability by clinicians, and we have found that Brainomix 360 Stroke merits scale up.